Pershing Square Sohn Cancer Research Alliance Prize For Young Investigators

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Pershing Square Sohn Cancer Research Alliance is taking applications for its Prize for Young Investigators in Cancer Research.

The prize of $200,000 per year for up to three years is awarded annually to at least five New York City-based scientists, enabling them to continue to pursue research at a stage when traditional funding is lacking. Each prize winner is also given a mentor in the pharmaceutical industry and the opportunity to present his or her work to scientific and business audiences.

In May 2015, PSSCRA awarded the prize to six winners: Timothy Chan, of Memorial Sloan Kettering Cancer Center; Arvin Dar, of the Icahn School of Medicine at Mount Sinai; Evripidis Gavathiotis, of Albert Einstein College of Medicine; Moritz Kircher, of MSKCC; Christine Mayr, of MSKCC; and Sohail Tavazoie, of The Rockefeller University.

In order to apply, applicants must have between two and eight years of experience running their own laboratories and must have a Ph.D., M.D., or M.D.-Ph.D. or equivalent. The deadline to submit a letter of intent is Nov. 9.

More details on the application process, including full eligibility criteria, are available on their website.

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login